血管活性物质与高血压的相关性研究  

Relationship of Vasoactive Substences and Hypertension

作　　者：章洪英[1] 朱立群[1] 戴颖楠[2] 李元十[1] 韩颖[1] 陈叶萍[1] 富路[1] 

机构地区：[1]哈尔滨医科大学附属第一医院,黑龙江哈尔滨150001 [2]哈尔滨医科大学附属第四医院,黑龙江哈尔滨150001

出　　处：《现代生物医学进展》2014年第28期5536-5538,共3页Progress in Modern Biomedicine

基　　金：黑龙江省教育厅基金面上项目(11521151)

摘　　要：目的:研究尾加压素Ⅱ(Urotensin-Ⅱ,U-Ⅱ)、内皮素(Endocilin,ET)、肾上腺素质素(Adrenomedullin,ADM)在高血压患者血浆中含量的变化并探讨其临床意义。方法:采用放射免疫法测定40例正常人和120例原发性高血压(所有患者既往未服用过降压药物)患者血浆中尾加压素、内皮素、肾上腺素质素的血浆含量。结果:高血压患者血浆中U-Ⅱ、ET及ADM含量明显高于正常对照组(3.275±1.257 pmol/L vs 1.802±0.639 pmol/L,P<0.01),(65.884±10.882 vs 51.831±6.488 pmol/L),(38.467±10.496 vs21.319±5.646 pmol/L)。患者血浆中U-Ⅱ水平与收缩压(r=0.371,P<0.01)及舒张压(r=0.262,P<0.01)水平呈正相关。血浆中U-Ⅱ水平与ET水平无显著相关性(rET=0.08,P>0.05),血浆中U-Ⅱ水平与ADM水平正相关(rADM=0.253,P<0.05)。结论:多种血管活性物质共同参与高血压的病理生理过程。U-Ⅱ、ET及ADM的含量变化可能作为高血压严重程度的指标。Objective： To observe the changes of plasma urotensin-Ⅱ, ET and ADM levels in patients with hypertension and to illustrate clinical significance of its changes. Methods： 120 patients with HP and 40 age and gendermatched control subjects were studied. Plasma U-Ⅱ, ET and ADM levels of 120 patients with HP and 40 control subjects were measured by radioimmunoassay. Results： The plasma U-Ⅱ, ET and ADM levels were significantly higher in patients with HP than that in control subjects （3.275± 1.257）VS（1.802±0.639）pmol/L, （65.884±10.882 vs 51.831±6.488 pmol/L）, （38.467± 10.496 vs 21.319±5.646 pmol/L）. The plasma U-Ⅱ levels have direct correlation to systolic pressure （r=0.371, P〈0.01） and diastolic pressure （r=0.262, P〈0.01）. The plasma U-Ⅱ levels have no correlation to ET levels （rET=0.08, P〉0.05）, but have direct correlation to ADM levels（rADM=0.253, P〈0.05）. Conclusion： In the process of hypertension, plasma levels of U-Ⅱ, ET and ADM showed gradually increasing changes. U-Ⅱ, ET and ADM might play a certain role in the pathophysiology of liP. The plasma levels of U-Ⅱ, ET and ADM maybe assess the severity of liP.

关 键 词：高血压 尾加压素Ⅱ 内皮素 肾上腺髓质素 

分 类 号：R544.1[医药卫生—心血管疾病]